Charles Lee
Company: AstraZeneca
Job title: Executive Director, Regulatory Affairs, Cardiovascular, Renal & Metabolism
Seminars:
Navigating Regulatory Pathways in an Evolving Multi-Drug CKD Treatment Landscape 11:00 am
Overview of shifts in CKD regulatory guidelines, recent endpoint changes, and the impact of scientific advances on clinical trial requirements Examination of how agencies are adapting endpoint standards to incorporate patient-reported outcomes, new biomarkers, and combination therapies for more patient-centered trials The role of CKM Syndrome in endpoint and outcome selection within CKD trials Exploring…Read more
day: Day Two Track 2
Panel & Audience Discussion: Enhancing Diversity in CKD Clinical Trials: What is Needed, What is Working, & What is Next? 11:30 am
Explore initiatives that have increased participation of underrepresented groups in CKD clinical trials where these efforts have yielded more inclusive trial populations Discuss the importance of diverse representation in trials for generating more accurate and generalizable data ensuring that treatments are effective across all demographics Explore new and emerging methods for ensuring diverse trial participation,…Read more
day: Day Two Track 2